podcasts
EPR Podcast Episode 1 – Richard Daniell, Teva Pharmaceuticals
Learn about current and future European pharmaceutical supply chains from Richard Daniell at Teva Pharmaceuticals in European Pharmaceutical Review’s first podcast.
List view / Grid view
Supply Chain
article
Building the UK’s domestic pharma manufacturing capability
In this article, Rich Quelch, Global head of marketing at Origin, discusses how the UK’s pharmaceutical supply chain could be adapted to increase its resilience to future disruptions and the challenges in doing so.
news
Adding vesicles to cell-free gene expression (CFE) systems increases yield
Enriching cell-free gene expression system extracts with membrane bound vesicles can significantly increase their ability to produce protein-based products, shows study.
article
Expediting the set-up of a manufacturing site: Rukobia case study
In this article, learn from GlaxoSmithKline’s and ViiV Healthcare’s team as they discuss the key elements that enabled them to build and set up a dedicated manufacturing facility for Rukobia in only 15 months.
article
COVID-19 vaccine rollout: a logistics success story
The dedication of the science community and healthcare workers in the fight against COVID-19 has been unwavering and justly praised. Yet logistics workers and the industries that support it have also achieved tremendous feats to support the resulting aid. Here, Zoe McLernon, Multimodal Policy Manager at Logistics UK, highlights the…
article
Implementation of trending charts in analysis of inventory pattern
Information is king – and real-time data regarding material stock movements is essential for effective inventory management. Here, Mostafa Eissa from Cairo University demonstrates the use of statistical processing control techniques for monitoring material mobility and how this could benefit the pharma industry.
article
Plasma-derived therapies require a mastery of advanced bioproduction techniques
Plasma-derived therapies and medicines provide life-changing treatments for patients around the world who suffer from serious, and often rare, diseases that affect the immune system or result from non-functioning proteins in blood plasma. Carole Resman, Executive Vice President Production at LFB, describes the complex and highly regulated manufacturing process of…
news
Biologics CDMO market to double in value by 2026, suggests report
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
video
On-demand webinar: Optimising MALDI-TOF for filamentous fungi ID
Challenges and solutions to adopting MALDI technology for filamentous fungi ID with emphasis on sample preparation and database development.
news
Biotech and pharma services outsourcing market to be worth over $91bn by 2028
A new report suggests the global biotechnology and pharmaceutical services outsourcing market will grow because of the pandemic and rising drug development costs and R&D investments.
webinar
Quality Risk Management tools to improve data integrity in micro QC
12 April 2021 | By Charles River Laboratories
Watch this on-demand webinar with Jordi Iglesias to learn how you can improve the data integrity of your microbiological QC assays.
news
Celonic to produce 100 million doses of CureVac’s COVID-19 vaccine candidate
Production of CureVac’s CVnCoV vaccine will take place in Germany, with over 50 million doses expected to be produced in 2021.
whitepaper
Whitepaper: Advantages of single-layer film versus multilayer film
This paper takes a closer look at plastic storage bags for bioprocesses focusing on a shift from multilayer to single-layer storage solutions.
news
African Union to receive 220 million doses of Janssen COVID-19 Vaccine
The African Vaccine Acquisition Trust (AVAT) has entered into an advanced purchase agreement for 220 million doses of Janssen COVID-19 Vaccine.
news
GSK to provide fill and finish capacity for Novavax’ COVID-19 vaccine
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
